Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

Research and Innovation Action · Running

BUCCAL-PEP Development of a multifunctional biomaterial patch for buccal delivery of peptide-analogue treatments

Coordinator
University College Dublin, National University of Ireland, Dublin, Ireland
Runs
1 January 2023 to 31 December 2026
Status
Running
EU funding
€4.0m
Total cost
€4.0m
Partners
9 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101091765

What the project is doing

In the project's own words, from its summary on CORDIS.

Oral delivery of peptide-analogues (a macromolecule) is one of the great challenges in pharmaceutical research. Thus far, only five peptide-analogues have been converted to oral formulations such as tablets/capsules and all face distinct challenges including low bioavailability, dosage control, patient administration inconvenience and restrictions in use (e.g. undesirable food interactions). The BUCCAL-PEP consortium will join hands to develop a multifunctional biomaterial patch which allows, for the first time, buccal (in the cheek) delivery of peptide-analogue therapies, thereby overcoming these challenges through unique integration of a permeation enhancer (SDC) with biomaterials and a peptide-analogue.

The novel formulation enables peptides to diffuse across the mucosal multilayer, thereby effectively achieving their intended pharmacological response. The novel approach will result in an improved quality of patient life and increased treatment compliance. Within this project, the consortium will design, select and manufacture a lead product (with Type 2 Diabetes as showcase indication) that will be validated for performance in in vivo large animal studies.

Additionally, a Health Technology Assessment will be performed to support the development an evidence-based value proposition and aid in the development of a commercialisation strategy. The final deliverable of the project is a patch that is pre-clinically validated and ready for clinical trials in the desired showcase indication. Overall, the BUCCAL-PEP project will provide a platform technology for oromucosal delivery of peptide-analogues that will be suitable for a broad range of experimental- and approved peptides-analogues therapies across a multitude of disease indications.

BUCCAL-PEP will enable novel peptide-based treatments to emerge, which otherwise might not have reached the market due to incompatibility with the currently available administration routes.

Who is involved

OrganisationCityCountryRole
University College Dublin, National University of Ireland, DublinDublinIrelandCoordinator
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Labtec GmbHLangenfeldGermanyThird party
Danmarks Tekniske UniversitetKongens LyngbyDenmarkParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
AdhexpharmaParisFranceParticipant
Catalyze B.V.Amsterdam-DuivendrechtNetherlandsParticipant
Universidade De AveiroAveiroPortugalParticipant
Cambridge Innovation Technologies Consulting LimitedCambridgeUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI